Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.53 |
| ▸ | CDK7 | P50613 | 5/20 | 0.43 |
| ▸ | CCNH | P51946 | 5/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.37 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19103316 | 0.90 | EGFR (0.43) | EGFRJAK2JAK1ERBB2ERBB3 | |
| SCHEMBL19103258 | 0.86 | EGFR (0.52) | EGFRCDK7CCNHERBB2ERBB3 | |
| SCHEMBL19103263 | 0.85 | EGFR (0.46) | EGFRJAK2ERBB2ERBB3ERBB4 | |
| SCHEMBL19103269 | 0.84 | EGFR (0.57) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL17384789 | 0.84 | EGFR (0.52) | EGFRCDK7CCNHCCNKMNAT1 | |
| SCHEMBL19103262 | 0.83 | EGFR (0.44) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL19103274 | 0.83 | EGFR (0.53) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL19103272 | 0.82 | EGFR (0.51) | EGFRJAK2JAK1ERBB2ERBB3 | |
| SCHEMBL22510191 | 0.82 | EGFR (0.49) | EGFR | |
| SCHEMBL19103286 | 0.82 | IGF1R (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885CDK7 263/4885CCNH 1237/4885 |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885CDK7 263/4885CCNH 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.